Cognition Therapeutics reports promising Phase 2 results for CT1812 in dementia with Lewy bodies

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage pharmaceutical company focused on neurodegenerative disorder treatment, has reported highly encouraging Phase 2 trial results for CT1812, a ... Read More